E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers S > Headlines for SkyePharma plc > News item
Published on 11/10/2006 in the Prospect News Biotech Daily.

Jefferies puts SkyePharma at buy

SkyePharma plc was given a buy rating by Jefferies & Co., Inc. analyst Robin Campbell. The analyst cut the company's price target to 40p from 65p, downgraded DepoDur forecasts and removed all Propofol expectations. Shares of the London-based pharmaceutical company were up 2 cents, or 0.56%, at $4.28. (Nasdaq: SKYE)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.